MEVION S250i Selected by Jinshazhou Hospital to Equip New Proton Therapy Center in Guangzhou, China
Mevion Medical Systems is pleased to announce it has signed an agreement for the sale of a MEVION S250i Proton Therapy System® with HYPERSCAN® Pencil Beam Scanning to Jinshazhou Hospital of Guangzhou University of Chinese Medicine . This will be the first compact proton therapy system in the Guangdong-Hong Kong-Macau Greater Bay Area. The signing ceremony was held on December 20, 2019, at Jinshazhou Hospital and joined by nearly one hundred Chinese and international radiation oncology experts and hospital executives.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200116005186/en/
The MEVION S250i system will be incorporated into the hospital’s world-class International Cancer Center in Guangzhou and is expected to begin treatment in 2021. Guangzhou is the capital city of the Guangdong province, which has a population of over one hundred million. The International Cancer Center is a joint effort between Jinshazhou Hospital and the ICON Group , Australia’s leading cancer care service provider. Led by Yang Wang, Ph.D., an internationally renowned medical physicist and the Vice President of Jinshazhou Hospital and Director of the International Cancer Center, the Center is equipped with cutting-edge medical technologies and an experienced medical team at the forefront of the cancer research. The University of Wollongong in Australia will also collaborate with the Center to provide medical physics training and education.
Proton therapy is an advanced form of radiation therapy that reduces unnecessary radiation dose to healthy tissue and prevents complications and secondary cancers. Mevion’s leading HYPERSCAN Pencil Beam Scanning technology further enhances these benefits with a faster and sharper dose delivery, which can be collimated layer-by-layer to provide a more precise and conformal dose to the tumor.
“We are pleased to be partnering with Mevion to make proton therapy available to benefit cancer patients in South China,” said Wensheng Liu, President of Jinshazhou Hospital. “MEVION S250i system is the most advanced proton therapy system available today and represents the best overall proton therapy solution. Its addition will position Jinshazhou Hospital as a world-class radiation therapy center. We look forward to elevating our cancer treatment, research capabilities, and medical education to the next level with protons.”
“It is exciting that the International Cancer Center and ICON Group will be able to utilize the most advanced proton technology provided by Mevion,” said Mark Middleton, CEO of ICON Group. “I believe the collaboration between Jinshazhou Hospital, ICON Group, Mevion, and University of Wollongong will have a bright future.”
“Mevion pioneered the world’s first compact single-room proton therapy system,” said Lawrence Yuan Tian, Ph.D., Chairman of Mevion Medical Systems. “Since its founding, Mevion has been leading the revolution of compact proton therapy as this advanced cancer treating technology gains widespread global adoption. We are proud to partner with Jinshazhou Hospital and ICON Group to bring the most precise radiation therapy to patients in the Greater Bay Area and beyond.”
The sale of a MEVION S250i system to Jinshazhou represents another concrete step in Mevion’s ambitious and ongoing expansion in China and the APAC region. "Combining the technical advantages of our product with a strong China team, Mevion is well-positioned to tap the fast-growing proton market in China,” said Tina Yu, Ph.D., CEO of Mevion Medical Systems. “Elite medical institutions in China have signed framework agreements with us in the past year, and we are on track to deliver our accelerator to Allcure Kangtai in 2020. Our collaboration with Jinshazhou Hospital marks another significant milestone in Mevion’s global growth."
About Mevion Medical Systems
Mevion Medical Systems, Inc. is the leading provider of compact proton therapy systems for use in radiation treatment for cancer patients. Mevion is based in Littleton, Massachusetts, with a presence in Europe and Asia. For more information, please visit www.mevion.com .
About Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
MN-PIPER-SANDLER7.8.2020 20:57:13 CEST | Press release
Piper Sandler Advises Momentive Performance Materials on the Sale of its Consumer Sealants Business to Henkel Corporation
ENA-INVESTMENT-CAPITAL7.8.2020 13:02:10 CEST | Press release
ENA Investment Capital Publishes Open Letter to Ontex Shareholders
MD-TAKEDA7.8.2020 11:30:07 CEST | Press release
Novavax and Takeda Announce Collaboration for Novavax’ COVID-19 Vaccine Candidate in Japan
CA-ANDERSEN-GLOBAL7.8.2020 10:05:05 CEST | Pressemeddelelse
Andersen Global indgår samarbejdsaftale med CFA Afrique i Burkina Faso
SES7.8.2020 07:32:11 CEST | Press release
SES S.A.: Half Year 2020 Results
CO-WESTERN-UNION6.8.2020 22:49:11 CEST | Press release
Western Union Stands in Solidarity with Lebanon
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom